BKS-db MASH Models

Gout/Hyperuricemia Models and Efficacy Services
Monosodium Urate (MSU)-induced Gouty Arthritis ModelsUrate Oxidase Knockout (Uox-KO) Gout Models
Hyperlipidemia Models and Efficacy Services
hPCSK9-UTR ModelshPCSK9 Models
Atherosclerosis Models and Efficacy Services
Ldlr KO ModelsApoE KO Models
Liver Disease Models and Efficacy Services
CCl4-induced Liver Fibrosis ModelsHFD+CCl4-induced MASH ModelsBKS-db MASH ModelsB6-Alms1-del MASH ModelsOther MASH Models
Type II Diabetes Models and Efficacy Service
HFHSD+STZ Induced Diabetes ModelsBKS-db
Obesity Models and Efficacy Services
Wild Mouse 750C57BL/6-Alms1-del45% HFHSD Induced Obesity(DIO) models60% HFD Induced Obesity (DIO) models

Study Outline

图片1.png

Figure 1. Overview of BKS-db mouse models.


Data Validation

1. Body Weight 

图片2.png

Figure 2. Weight gain in BKS-db MASH mice after WD induction. Data are presented as Mean±SD, n=5-10.


2. Blood lipid levels

图片2-1.png

Figure 3. After 4 weeks of WD induction, BKS-db MASH mice had higher blood lipid levels than BKS-db normal diet mice. The data are shown as Mean±SD, with n=10-20. **, P<0.01; ***, P<0.001; ****, P<0.0001. by one way ANOVA with Dunnett's post hoc test.


3. Liver enzymes

图片3.png

Figure 4. After 4 weeks of WD induction, BKS-db MASH mice had increased liver enzyme levels compared to BKS-db mice on a normal diet.The data are shown as Mean±SD, with n=10-20. *, P<0.05; **, P<0.01; ****, P<0.0001.  by one way ANOVA with Dunnett's post hoc test.


4. Liver Phenotype

图片4.png

Figure 5. After 4 weeks of WD induction, BKS-db MASH mice developed a severe fatty liver phenotype. The data are shown as Mean±SD, n=5. ****，P<0.0001; by unpaired t test.


5. Histopathology

图片5.png

Figure 6. BKS-db MASH mice showed a more severe inflammatory phenotype, including lipid accumulation and cellular vacuole-like lesions, after 4 weeks of WD induction.


6. Expression of inflammation, fibrosis-related biomarkers

图片6.png

Figure 7. After 4 weeks of WD induction, the expression levels of inflammation, fibrosis-related biomarkers were raised in BKS-db MASH mice. The data are shown as Mean±SD, n=5. *，P<0.05；**，P<0.01；****，P<0.0001; by unpaired t test. 


Efficacy data

1. Body Weight

图片7.png

Figure 8. Semaglutide significantly reduced the body weight and body weight change rate in BKS-db MASH model. Data are presented as Mean±SD. ***, p<0.001by one way ANOVA with Tukey's post hoc test.


2. Fasting Blood Glucose

图片8.png

Figure 9. Semaglutide significantly reduced fasting glucose in the BKS-db MASH model. Data are presented as Mean±SD, n=5~10. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


3. Liver function

图片9.png

Figure 10. Semaglutide Significantly Improved Liver Function and Dyslipidemia in BKS-db MASH Model. Data are presented as Mean±SD, n=5-10. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


4. Liver weight

图片10.png

Figure 11. Semaglutide significantly reduced liver weight and the liver to body weight ratio in BKS-db MASH model. Data are presented as Mean±SD, n=5~8. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


5. Histopathology

图片11.png

Figure 12. Semaglutide significantly improved the hepatic steatosis, inflammation and ballooning in BKS-db MASH mode. Data were presented as Mean±SD, n=5~8. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


TALK WITH OUR EXPERTS

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。